James' Vision for Bridge Biotherapeutics: Advancing Pulmonary Fibrosis, Lung Cancer, and Immunology Treatments| James Lee, CEO , Bridge Biotherapeutics Inc. 00:10:00
James Lee is the Founder and CEO of Bridge Biotherapeutics, a South Korea-based biotech company focused on developing novel therapeutics for conditions with high unmet medical needs, including fibrotic diseases and cancers. Under his leadership, Bridge Biotherapeutics has advanced several drug candidates, including BBT-877, an autotaxin inhibitor in Phase 2 trials for idiopathic pulmonary fibrosis (IPF). The company’s strategy involves a global approach to drug development, with partnerships and collaborations across the U.S., Europe, and China.
